Pharmaceutical service provider Solvias has acquired Confarma, a global provider of scientific services, and its subsidiary Confarma France. The acquisition is a key component of the forward-looking growth strategy of Solvias and Confarma.
Solvias is pursuing a long-term growth strategy with the aim of expanding its extensive range of services for pharmaceutical companies. By acquiring the Confarma Group, Solvias and Confarma are strengthening their market position in the highly competitive quality control segment and increasing the range of analytical services they can offer their partners in pharmaceuticals, biotechnology and life science.
Two successful and established brands are coming together via this acquisition to form a single group, yet each will continue to have an independent presence on the market. Maintaining continuity is therefore the overriding concern.
"We are convinced that the clients of both Solvias and Confarma will benefit in the long run from the added value generated by the two companies coming together,” said Dr. Hansjörg Walther, CEO of Solvias. “We are consolidating our position as a dependable partner of pharmaceutical companies throughout the entire product life cycle."
The individual steps of the integration process will be defined in detail in the coming months.
"We want to unleash the great potential for synergy that the merger offers by learning from each other and implementing the knowledge gained as group-wide best practice," said Walther. "And because our companies, Solvias and Confarma, are in a period of growth, the integration will not lead to any reduction in staff, but rather will create jobs. We firmly believe that the synergies realized will contribute to growth this year and be positively reflected in our results."